메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Ascletis Selects a Best-In-Class Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for Clinical Development

- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC35 was approximately 14 days, 6-fold longer than tirzepatide, which supports once-monthly subcutaneous (SQ) dosing in humans. - In head-to-head NHP studies, drug exposures of ASC35 intravenous (I.V.) and SQ administration were approximately 80% and 70% greater than tirzepatide I.V. and SQ administration, respectively. - ASC35 was approximately 4-fold more potent than tirzepatide for both GLP-1 receptor (GLP-1R) and GIP receptor (GIPR) in vitro. - ASC35 demonstrated approximately 71% greate
- 김갑성 기자
- 2025-10-13 08:10
Reach Surgical's OMNIBOT Performs First Urology Robotic Telesurgeries in Latin America

Advancing regional collaboration and surgeon training in remote robotic-assisted surgery SINGAPORE, Oct. 13, 2025 -- Reach Surgical, the Surgical Solutions division of Genesis MedTech, has facilitated the completion of two robotic telesurgeries using its OMNIBOT robotic-assisted system. Operating from Reach Surgical Institute (RSI) in Santiago, Dr. Roberto Vilches and Dr. Marcelo Kerkebe remotely performed a radical prostatectomy and a partial nephrectomy on patients at Meds Medical Center. These procedures mark an important milestone in advancing robotic t
- 김갑성 기자
- 2025-10-13 08:00
C-Ray Therapeutics (Chengdu) Co., Ltd Congratulates Partner Biokin Pharmaceutical on NMPA IND Approval of First Proprietary ARC Drug [177Lu]-BL-ARC001

CHENGDU, China, Oct. 11, 2025 -- C-Ray Therapeutics (Chengdu) Co.,Ltd proudly congratulates its strategic partner, Biokin Pharmaceutical, on receiving implied approval from the National Medical Products Administration (NMPA) for the clinical trial application of [177Lu]-BL-ARC001 Injection, the company's first radiopharmaceutical and a Class 1 innovative biologic. This milestone approval marks Biokin's entry into the fast-growing Radiopharmaceutical Drug Conjugate (RDC) field and reinforces its leadership in large-molecule oncology therapies (ADC/GNC/ARC). The company's flagship asset
- 김갑성 기자
- 2025-10-11 20:45
Third Indication for Kelun-Biotech's TROP2 ADC Sac-TMT Approved for Marketing by NMPA in EGFRm NSCLC Following Progression on EGFR-TKI Therapy

CHENGDU, China, Oct. 11, 2025 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) was approved for marketing by the National Medical Products Administration (NMPA) for its third indication, the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who progressed after treatm
- 김갑성 기자
- 2025-10-11 17:54
Sandstone Easydrip™ Plus Pen Needles Debut in Turkey -- Patent‑Protected Hexagonal Hub for Comfort and Control

[ 메디채널 김갑성 기자 ] Large‑platform hexagonal hub (Hextra Tech) offers superior stability and ease of grip; ISO 13485 & CE certified; launched by a leading regional diabetes distributor and 4,000+ pharmacies ISTANBUL, Oct. 11, 2025 -- Sandstone Medical — a SteriLance Medical sub‑brand focused on diabetes self‑injection — today announced the introduction of its Easydrip™ Plus pen needles into the Turkish market through a leading regional diabetes distributor with a nationwide pharmacy network. The launch is already unlocking interest from neighbouring Middle‑East markets.
- 김갑성 기자
- 2025-10-11 15:50
健康管理の主導権は自分にある？アジアのトップ医療専門家が「イエス」と回答、その理由と方法を明かす

11の国/地域から100人を超えるヘルスケア・リーダーがAPSMI Summitに集まり、ヘルスケアにおける消費者主導のセルフケアを推進します。サミットでは、回復力のある医療システムを支援するための知識とツールを個人に提供することの重要性が強調されています。バリ（インドネシア）、2025年10月11日 -- アジア太平洋の[ 메디채널 김갑성 기자 ] 11の国/地域から100人を超えるヘルスケア・リーダーがバリで開催されたAsia Pacific Self-Medication Industry (APSMI) Summit 2025に集まり、同地域のセルフケア・ソリューションを推進しました。「ヘルスケアにおけるセルフケア：共通のビジョンから共通の行動へ（Self-Care in Healthcare: From Shared Vision to Shared Action）」というテーマで、今回のサミットは、アジア太平洋地域全体で共通の理解を実際的かつ証拠に基づく行動に変える必要性を強調しました。World Health Organization（WHO）によって認められているセルフケアは、個人が健康を維持し、病気を予防し、責任を持って状態を管理する力を与え、コミュニティと医療システムの両方を強化します。
- 김갑성 기자
- 2025-10-11 06:42
Circulation Publishes 6-Month Outcomes from First-in-Human VCAS Trial of FieldForce™ Pulsed Field Ablation System: 82% Freedom from VT/VF Recurrence and 98% Reduction in Burden

Findings presented at the International VT Symposium and published simultaneously in Circulation. CARDIFF-BY-THE-SEA, Calif. and PHILADELPHIA, Oct. 11, 2025 -- Field Medical, Inc. today announced that Circulation has published six-month outcomes from the Ventricular Catheter Ablation Study (VCAS), the first-in-human evaluation of its FieldForce™ Ablation System for ventricular tachycardia (VT). Results were also presented as a late-breaking trial at the 20th Annual International Symposium on Ventricular Arrhythmias (VT Symposium). Results at Six MonthsVCAS is a p
- 황정호 기자
- 2025-10-11 04:35
Roche Collaborates with OASES to Drive Primary Healthcare Transformation and Innovation, Strengthening Hong Kong's Position as a Global Healthcare Hub

HONG KONG, Oct. 10, 2025 -- Roche announced its strategic collaboration with the Office for Attracting Strategic Enterprises (OASES) to accelerate healthcare innovation and strengthen Hong Kong's role as a leading hub for life sciences and medical technology in the Asia Pacific region. As part of this announcement, Roche will strengthen its presence in Hong Kong over the next five years. The collaboration is a joint effort between its Pharmaceutical and Diagnostics divisions, with each providing distinct perspectives and advantages. This commitment reflects Roche's confidence i
- 김갑성 기자
- 2025-10-10 21:11
알라마 바이오사이언스, NULISAqpcr™ BD-pTau217 분석법 출시: 알츠하이머병 치료를 목적으로 한 비침습적 뇌 내 바이오마커 검출 방식의 획기적인 진전

탁월한 민감도와 특이도를 보장하는 혈액 검사 방식의 새로운 분석법이 등장하면서 진일보한 분석법을 개발하기가 수월해질 전망이다. 프리몬트, 캘리포니아주, 2025년 10월 10일 -- 가장 초기에 질병을 발견할 수 있는 정밀 단백질체학 기술을 선도하는 기업인 알라마 바이오사이언스(Alamar Biosciences)가 오늘 NULISAqpcr™ 뇌 유래 인산화 타우(BD-pTau217) 분석법을 출시한다고 발표했다. 혈액 검사만으로 알츠하이머병과 기타 타우병증 연구의 핵심 바이오마커인 BD-pTau217 수치를 측정할 수 있는 획기적인 진전이 이뤄진 것이다. 이 동종 최초의 분석법은 시판 중인 제품 중 유일한 뇌 내 타우 단백질 단일 검사 솔루션으로서, 신경퇴행성 질환 연구의 정확도와 중추신경계 특이성에 대한 새로운 기준을 제시한다. 알라마의 독점 NULISA™ 플랫폼을 기반으로 하는 NULISAqpcr BD-pTau217 분석법에서는 비침습적 방식으로 혈장, 혈청, 건조 혈반 같은 검체를 채취하며, 전례 없는 수준의 민감도와 특이도가 보장된다. 이 분석법을 사용하면 뇌척수액(CSF)을 채취하거나 PET 영상을 촬영할
- 김갑성 기자
- 2025-10-10 19:39
Vietnam's Visionary Leaders Redefine Success at the Asia Pacific Enterprise Awards 2025

HO CHI MINH CITY, Vietnam, Oct. 10, 2025 -- Vietnam's most visionary leaders and trailblazing enterprises took center stage at the Asia Pacific Enterprise Awards (APEA) 2025 Vietnam, held on 9 October 2025 at the GEM Center, Ho Chi Minh City. Organized by leading regional NGO Enterprise Asia, the prestigious awards program honored businesses and business leaders who are reshaping industries, embracing innovation, and driving sustainable growth. With the theme 'Showcasing Future-Ready Enterprises', this year's APEA celebrated organizations and leaders who are future-proofing the
- 김갑성 기자
- 2025-10-10 15:43

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-10-18_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 18일 18시 00분